• Pacific Biosciences of California, Inc. Announces First Quarter 2021 Financial Results

    Source: Nasdaq GlobeNewswire / 29 Apr 2021 15:05:01   America/Chicago

    MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2021.

    Record first quarter revenue reflects a strong start to 2021

    Revenue for the first quarter of 2021 was $29.0 million, representing an 86% increase compared with $15.6 million for the first quarter of 2020. The Company placed 41 Sequel II/IIe systems during the first quarter of 2021 compared to 11 Sequel II systems placed in the first quarter of 2020 and 35 Sequel II/IIe systems placed during the fourth quarter of 2020, bringing the total installed base of Sequel II/IIe systems to 244 as of March 31, 2021, compared with 125 as of March 31, 2020 and 203 as of December 31, 2020. Instrument revenue for the first quarter of 2021 was $14.9 million, compared with $4.0 million for the first quarter of 2020. Consumables revenue for the first quarter of 2021 was $10.4 million compared with $8.3 million for the first quarter of 2020. Service and other revenue for the first quarter of 2021 was $3.7 million compared with $3.3 million for the first quarter of 2020.

    Gross profit for the first quarter of 2021 was $13.0 million, representing a 73% increase compared with $7.5 million for the first quarter of 2020. Gross margin for the first quarter of 2021 was 45%, compared to 48% for the first quarter of 2020.

    Operating expenses totaled $46.7 million for the first quarter of 2021, compared to $40.2 million for the first quarter of 2020. Operating expenses for the first quarter of 2021 and first quarter of 2020 included non-cash stock-based compensation of $9.2 million and $3.5 million, respectively.

    Net loss for the first quarter of 2021 was $87.4 million, compared to a net income of $1.3 million for the first quarter of 2020. The net loss for the first quarter of 2021 was largely driven by the repayment of $52 million of Continuation Advances to Illumina in the first quarter of 2021 as a result of the investment from SoftBank. First quarter 2020 included $34 million in other income from Continuation Advances from Illumina.

    Basic and diluted net loss per share for the first quarter of 2021 was $0.45 per share compared to basic and diluted net income of $0.01 per share for the first quarter of 2020.

    In February 2021, SB Northstar LP, a subsidiary of SoftBank Group Corp., made an investment of $900 million in convertible senior notes to support the Company’s future growth initiatives. Cash, cash equivalents and investments, excluding short and long-term restricted cash, at March 31, 2021 totaled $1,160.3 million, compared to $318.8 million at December 31, 2020.

    Updates since our last earnings release

    • Released a new HiFi workflow and an updated software version that increases the number of reads at or above 99.9% accuracy, scales workflows to sequence hundreds to thousands of whole human genomes per year, and opens up more sample types to HiFi sequencing.
    • Shipped four additional Sequel IIe Systems to Children’s Mercy Kansas City, significantly increasing their whole genome sequencing capabilities to identify potential disease-causing variants for children living with undiagnosed diseases.
    • Deployed Sequel IIe systems at LabCorp to scale their capabilities to sequence SARS-CoV-2.
    • Announced Hannah Valantine, M.D., as a director nominee for election to the Board of Directors at this year’s annual meeting of stockholders; Dr. Valantine has decades of experience as Professor of Medicine at the Stanford University Medical Center and as the NIH Chief Officer for Scientific Workforce Diversity.

    “PacBio is off to a great start in 2021 as we achieved record revenue in the first quarter that exceeded our expectations,” said Christian Henry, President and Chief Executive Officer. “We installed a record number of Sequel II Systems and recorded our fourth straight quarter of sequential growth. In the first quarter, we made excellent progress on our strategic initiatives, and we remain in the early stages of the impact that PacBio sequencing can have on human health.”

    Impact of COVID-19 Pandemic

    Financial results for the first three months of 2020 were negatively impacted as multiple customers postponed system deliveries, and the financial results for much of 2020 were further impacted as several customers shut down or limited operations for various periods to help curb the spread of the COVID-19 pandemic. Instrument utilization largely returned to normal by the fourth quarter of 2020, and we subsequently have not seen significant issues with deliveries or operations at customer sites. This resulted in higher product revenues of $25.3 million for the first quarter of 2021 compared to $12.3 million for the same period of 2020. Uncertainties associated with the pandemic, including recent resurgences in infection rates, may cause further impacts to our operations and financial results.

    Quarterly Conference Call Information 

    Management will host a quarterly conference call to discuss its first quarter ended March 31, 2021 results today at 4:30 p.m. Eastern Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330, using Conference ID # 9858326. The call will be webcast live and will be available for replay at Pacific Biosciences’ website at https://investor.pacificbiosciences.com/.

    About Pacific Biosciences

    Pacific Biosciences of California, Inc. (NASDAQ: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

    Forward-Looking Statements

    All statements in this press release that are not historical are forward-looking statements, including, among other things, our preliminary financial results for the first quarter ended March 31, 2021, including our revenue, instrument revenue, consumable revenue and service and other revenue and our installed instruments during the quarter, sequential growth and factors such as limits or interruptions in chip supplies that could impact our growth, customer interest in SMRT Sequencing with HiFi reads, sales momentum, the accuracy, throughput and benefits of HiFi reads and the capabilities of SMRT sequencing, progress on Company initiatives and the impact the Company can have on human health, the impact of COVID-19 on our business, the nomination of Dr. Valantine to our Board, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.

    The condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in the Pacific Biosciences’ Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission.

    Contacts

    Investors:
    Todd Friedman
    650.521.8450
    ir@pacificbiosciences.com

    Pacific Biosciences of California, Inc.
    Unaudited Condensed Consolidated Statement of Operations
    (amounts in thousands, except per share amounts)

     Three Months Ended
     March 31, 2021 December 31, 2020 March 31, 2020
    Revenue:        
    Product revenue$25,303  $23,626  $12,293 
    Service and other revenue 3,694   3,510   3,305 
    Total revenue 28,997   27,136   15,598 
    Cost of Revenue:        
    Cost of product revenue 12,697   12,550   5,421 
    Cost of service and other revenue 3,323   3,185   2,689 
    Total cost of revenue 16,020   15,735   8,110 
    Gross profit 12,977   11,401   7,488 
    Operating Expense:        
    Research and development 20,548   17,425   15,250 
    Sales, general and administrative 26,139   17,953   24,947 
    Total operating expense 46,687   35,378   40,197 
             
    Operating loss (33,710)  (23,977)  (32,709)
    Gain from Reverse Termination Fee from Illumina —   98,000   — 
    Gain (loss) from Continuation Advances from Illumina (52,000)  —   34,000 
    Interest expense (1,789)  —   (267)
    Other income, net 64   912   238 
    Net income (loss)$(87,435) $74,935  $1,262 
             
    Net income (loss) per share        
    Basic$(0.45) $0.40  $0.01 
    Diluted$(0.45) $0.37  $0.01 
    Weighted average shares outstanding used in calculating net income (loss) per share        
    Basic 194,790   186,013   153,453 
    Diluted 194,790   203,822   155,855 
                

    Pacific Biosciences of California, Inc.
    Unaudited Condensed Consolidated Balance Sheets
    (amounts in thousands)

     March 31,  December 31,
     2021 2020
    Assets   
    Cash and investments$1,160,319 $318,814
    Accounts receivable 12,906  16,837
    Inventory 16,268  14,230
    Prepaid and other current assets 5,623  4,870
    Property and equipment, net 24,207  24,899
    Operating lease right-of-use assets, net 29,162  29,951
    Restricted cash 4,336  4,336
    Other long-term assets 67  43
    Total Assets$1,252,888 $413,980
          
    Liabilities and Stockholders' Equity     
    Accounts payable$3,471 $3,579
    Accrued expenses 14,672  17,350
    Deferred revenue 15,294  10,290
    Operating lease liabilities 40,933  41,999
    Convertible senior notes, net 895,674  —
    Other liabilities 2,291  5,271
    Stockholders' equity 280,553  335,491
    Total Liabilities and Stockholders' Equity$1,252,888 $413,980
          

    Primary Logo

Share on,